MX2012003426A - Bacterias gram-negativas modificadas para su uso como vacunas. - Google Patents

Bacterias gram-negativas modificadas para su uso como vacunas.

Info

Publication number
MX2012003426A
MX2012003426A MX2012003426A MX2012003426A MX2012003426A MX 2012003426 A MX2012003426 A MX 2012003426A MX 2012003426 A MX2012003426 A MX 2012003426A MX 2012003426 A MX2012003426 A MX 2012003426A MX 2012003426 A MX2012003426 A MX 2012003426A
Authority
MX
Mexico
Prior art keywords
negative bacteria
vaccines
gram
modified gram
lps
Prior art date
Application number
MX2012003426A
Other languages
English (en)
Inventor
Jean-Pierre Gorvel
Gorvel Vilma Arce
Maite Iriarte
Ignacio Moriyon
Raquel Conde-Alvarez
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of MX2012003426A publication Critical patent/MX2012003426A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se relaciona con bacterias Gram-negativas que portan un gen inactivado que codifica una glicosiltransferasa involucrada en la síntesis del núcleo del LPS de dichas bacterias Gram-negativas, en donde dicho gen inactivado resulta en la síntesis de un LPS que tiene un núcleo modificado; estas cepas tienen una virulencia atenuada pero inducen una inmunidad humoral suficiente para asegurar la vacunación del hospedero.
MX2012003426A 2009-09-21 2010-09-21 Bacterias gram-negativas modificadas para su uso como vacunas. MX2012003426A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305879 2009-09-21
PCT/EP2010/063921 WO2011033129A1 (en) 2009-09-21 2010-09-21 Modified gram-negative bacteria for use as vaccines

Publications (1)

Publication Number Publication Date
MX2012003426A true MX2012003426A (es) 2012-08-03

Family

ID=41800489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003426A MX2012003426A (es) 2009-09-21 2010-09-21 Bacterias gram-negativas modificadas para su uso como vacunas.

Country Status (7)

Country Link
US (2) US8778655B2 (es)
EP (1) EP2480240B1 (es)
CN (1) CN102665739B (es)
BR (1) BR112012006417B1 (es)
ES (1) ES2612486T3 (es)
MX (1) MX2012003426A (es)
WO (1) WO2011033129A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248176B2 (en) * 2010-10-07 2016-02-02 The Texas A&M University System Controlled release vaccines and methods for treating Brucella diseases and disorders
ES2389066B1 (es) * 2011-03-25 2013-10-30 Instituto Científico Y Tecnológico De Navarra S.A. Método diva de diferenciación de animales vacunados frente a la brucelosis.
WO2016005390A1 (en) * 2014-07-10 2016-01-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Modified bacteria for improved vaccines against brucellosis
CN105137073A (zh) * 2015-08-06 2015-12-09 中国兽医药品监察所 牛布鲁氏菌胶体金抗体检测试纸条
CN105067812A (zh) * 2015-08-06 2015-11-18 中国兽医药品监察所 牛布鲁氏菌间接elisa抗体检测试剂盒
WO2017108515A1 (en) * 2015-12-21 2017-06-29 Universidad De Navarra Modified gram negative bacterial strains and uses thereof
WO2018023000A1 (en) * 2016-07-29 2018-02-01 The Regents Of The University Of Michigan Recombinant gram negative bacteria and methods of generating and utilizing same
CN106801029B (zh) * 2017-01-22 2020-05-01 山东大学 一株重组大肠杆菌及其在制备抗志贺氏菌的糖疫苗中的应用
CN108048383A (zh) * 2017-12-26 2018-05-18 西南大学 羊种布鲁氏菌per基因缺失菌株、其构建方法及应用
CN109142757A (zh) * 2018-11-02 2019-01-04 中国农业科学院兰州兽医研究所 一种布鲁氏菌间接elisa检测试剂盒
CN112625943B (zh) * 2020-12-02 2021-11-16 安徽农业大学 一种玉米用溶钾菌剂及其制备方法和应用
EP4295855A1 (en) * 2022-06-23 2023-12-27 Crazy Science & Business SL Lipopolysaccharide for use in the prevention and/or treatment of fetal malformations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3777893A (en) * 1992-02-25 1993-09-13 The Texas A & M University System Improved vaccin against brucella abortus
US6444445B2 (en) * 1998-01-22 2002-09-03 The United States Of America As Represented By The Secretary Of The Army Live vaccine against Brucellosis
WO2008095679A1 (en) * 2007-02-05 2008-08-14 Stichting Katholieke Universiteit Use of bartonella quintana derived lipopolysaccharide for the treatment of autoimmune, autoinflammatory or infectious diseases
CN101386831B (zh) * 2008-10-22 2010-12-01 中国农业大学 一种带有免疫标记的流产布鲁氏菌的重组菌及其应用

Also Published As

Publication number Publication date
US9034630B2 (en) 2015-05-19
EP2480240A1 (en) 2012-08-01
CN102665739B (zh) 2015-05-27
CN102665739A (zh) 2012-09-12
WO2011033129A1 (en) 2011-03-24
EP2480240B1 (en) 2016-11-02
BR112012006417A2 (pt) 2016-11-16
ES2612486T3 (es) 2017-05-17
US20140286996A1 (en) 2014-09-25
BR112012006417B1 (pt) 2019-11-19
US8778655B2 (en) 2014-07-15
US20120183576A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
MX2012003426A (es) Bacterias gram-negativas modificadas para su uso como vacunas.
DK2566507T3 (da) Biokonjugatvacciner med kapselformige grampositive bakterier
EP2545068B8 (en) Immunogenic composition or vaccine against gram-negative bacterial, for example neiserial, infection or disease
MX2011011505A (es) Vacuna neumococica y usos de la misma.
HK1142809A1 (en) Multimeric multiepitope influenza vaccines
MX349630B (es) Alfa-amilasas.
MX2013014109A (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
MX2016007939A (es) Nueva vacuna de adn dirigida contra msln para la inmunoterapia de cancer.
MX2011012234A (es) Plasmido libre de antibiotico.
PH12014502855A1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
CO6751260A2 (es) Vacunas basadas en omv contra infecciones por burkholderia
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
MX2013015198A (es) Vacuna del corona virus canino.
BR112012030659A8 (pt) Parvovírus vivo atenuado, vacina, e, métodos para a fabricação de uma vacina, e para a preparação de um parvovírus mutante
MY158910A (en) Surface modified silicic acid semi-gels
WO2012003361A3 (en) Nanoemulsion vaccines
WO2011122843A3 (ko) 어류의 연쇄구균증 예방용 혼합 불활성화 백신 및 그 제조방법
EP2482843A4 (en) PROCESS FOR IMPROVED VACCINE IMMUNOGENICITY
NZ717369A (en) Antibody titer-increasing agent using lactic acid bacterium
UA114511C2 (uk) Стійкий до ампіциліну текстуруючий штам молочнокислих бактерій
AP2010005446A0 (en) Inactivated live-attenuated bluetongue virus vaccine.
MX2011005281A (es) Vacuna marcadora de salmonella.
GB2515222A (en) Use of flagellin as a vaccine
EP2491142A4 (en) GENERATING AN IMMUNE RESPONSE TO REDUCE THE RISK OF DEVELOPING BRUCELLOSIS
NZ607792A (en) Improved vaccine compositions

Legal Events

Date Code Title Description
GB Transfer or assignment

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC

FG Grant or registration